Epstein-Barr virus epitopes (EBV epitopes)

Epstein-Barr virus (EBV) epitopes are specific peptide sequences derived from EBV-encoded proteins, such as EBNA1, LMP1, and LMP2, that serve as the primary recognition sites for the host immune system. These epitopes are critical for the activation of CD4+ and CD8+ T-cells, which control the persistent latent infection characteristic of EBV. In the context of EBV-associated malignancies and lymphoproliferative disorders, these epitopes are targeted by adoptive T-cell therapies and experimental vaccines to selectively eliminate virally infected cells. Beyond oncology, EBV epitopes have gained significant attention for their potential role in the pathogenesis of multiple sclerosis through mechanisms like molecular mimicry. Therapeutic strategies focus on enhancing the immune response against these epitopes or using them as diagnostic markers for viral load and immune competence. The clinical utility of EBV epitopes is highly dependent on the patient's HLA profile, which determines the efficiency of epitope presentation and subsequent immune surveillance.

Other names

Epstein-Barr virus antigensEBV-associated antigensEBV-specific peptidesEBV immunodominant epitopes

Adoptive immunotherapy using T-cells primed to recognize specific EBV epitopes to induce apoptosis in EBV-infected cells; induction of humoral and cellular immunity via vaccine-mediated epitope presentation; inhibition of viral replication by targeting enzymes involved in epitope processing.